(Q24814067)

4 July 2017

title

Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma (English)

1 reference

4 July 2017

main subject

phase II clinical trial

0 references

author

Ewert Schulte-Frohlinde

3

object named as

Ewert Schulte-Frohlinde

0 references

author name string

Stefan von Delius

1

1 reference

4 July 2017

Christian Lersch

2

1 reference

4 July 2017

Ewert Schulte-Frohlinde

3

1 reference

4 July 2017

Martina Mayr

4

1 reference

4 July 2017

Roland M Schmid

5

1 reference

4 July 2017

Florian Eckel

6

1 reference

4 July 2017

language of work or name

English

0 references

publication date

12 June 2005

1 reference

4 July 2017

1 reference

4 July 2017

volume

5

1 reference

4 July 2017

issue

1

0 references

page(s)

61

1 reference

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

4 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1180427

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1180427

Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1180427

A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1180427

Gallbladder and biliary tract carcinoma: A comprehensive update, Part 2.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1180427

Gallbladder and biliary tract carcinoma: A comprehensive update, Part 1.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1180427

Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1180427

Cholangiocarcinoma: Current concepts and insights

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1180427

Toxicity of a 24-hour infusion of gemcitabine in biliary tract and pancreatic cancer: a pilot study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1180427

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1180427

Biliary tract cancer: our experience with gemcitabine treatment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1180427

28 September 2017

Biliary tract cancers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1180427

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1180427

Gemcitabine: preclinical pharmacology and mechanisms of action.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1180427

Optimal two-stage designs for phase II clinical trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1180427

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

30 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-5-61

Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-5-61

A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-5-61

Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-5-61

Schedule-dependent antitumor effect of gemcitabine in in vivo model system

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15949047

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15949047

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase II trial of low-dose cyclophosphamide, leucovorin, high-dose 5-fluorouracil 24-hour continuous infusion and tamoxifen in advanced biliary tract cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15949047

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2407-5-61

1 reference

Dimensions Publication ID

4 July 2017

1045036840

0 references

PMC publication ID

1180427

0 references

1 reference